N/A
N=32
Assessment of Colonic Epithelial Integrity With Mucosal Impedance
Inflammatory Bowel Diseases
Bottom Line
View on ClinicalTrials.gov: NCT03165058 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Jun 2020
Primary outcome: Primary: Mucosal Impedance Values — 1139; 849; 891; 783 ohms
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- mucosal impedance (MI) testing (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vanderbilt University Medical Center
- Primary completion
- May 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mucosal Impedance Values |
1139; 849; 891; 783; 673; 699 | — |
| SECONDARY Difference in Inflamed and Normal Mucosa |
— | — |
Summary
In this study, the investigators propose to use mucosal impedance (MI), a minimally invasive technology, to detect mucosal damage (i.e. barrier dysfunction) based on mucosal conductivity changes in the colonic epithelium.
Eligibility Criteria
Inclusion Criteria
- Men and women over the age of 18 with a diagnosis of IBD (Ulcerative Colitis or Crohn's Disease)
- Men and women undergoing screening colonoscopy (typical age would be 50 or greater but there are exceptions)
Exclusion Criteria
- Age less than 18 years old
- Patients unable to give informed consent
- Patients with history of colonic surgeries
- Patients with history of colonic motility disorder
Data sourced from ClinicalTrials.gov (NCT03165058). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.